
RARITAN, NJ--Procrit (Epoetin alfa) has received marketing clearance by the FDA for use in reducing the need for allogeneic blood transfusions in anemic patients scheduled to undergo elective noncardiac, nonvascular surgery. Patients should be at high risk for perioperative transfusion with significant, anticipated blood loss. Procrit is not indicated for anemic patients who are willing to donate autologous blood.

